Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


Maculus Therapeutix Welcomes Privity FZ LLE And Prepares Capital Raise For Novel Drug Delivery Platform

Maculus Therapeutix, a preclinical-stage biopharmaceutical company which has developed a SINGLE injection delivery platform for diseases such as wet AMD (Age-related Macular Degeneration) and DME (Diabetic Macular Edema) instead of the standard 8-12 monthly injections, is pleased to welcome Privity FZ LLE as a partner and advisor for upcoming fundraising activities. Maculus plans to raise USD3 million with a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies.

Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, MacuBloc, capable of delivering any FDA approved drugs for Wet AMD / DME to the site of the disease, with unique suitability for targeted and extended delivery of drugs to the back of the human eyes, MacuBloc offers significant benefits to Wet AMD patients: a single intravitreal injection that lasts a year rather than the current monthly injections, and a potential reduction in inflammation, infection, doctor visits and total cost of care, compared to current practice.

Syed H Askari, PhD, Founder, Chief Executive Officer and CTO of Maculus Therapeutix, said, "We are very excited to welcome Privity in developing this unique product, which can bring such transformative treatment to those suffering from wet AMD and DME. Our product is designed to solve each of the challenges while significantly reducing the total cost of care. More importantly, our product makes it possible to replace the 10 injections with ONE injection for any FDA approved drug, a leap ahead of the current standard of care."

The approach will change the lives of 200 million patients worldwide who suffer from debilitating eye diseases. Current standards of care (8-12 monthly injections to the eyes for AMD and for DME) have numerous challenges: pain, inflammation, infection, loss of vision. Our product is designed to solve each of these challenges while significantly reducing the total cost of care. More importantly, our product makes it possible to replace the 10 injections by ONE injection for any FDA approved drug, a significant leap ahead of the current standard of care.

Sleem Hasan, Privity Founder and CEO, said, "Privity was founded to identify entrepreneurs with unique ideas and compelling value propositions, and Maculus fell right into this sweet spot, speaking straight at me as I had experienced diabetic retinopathy personally and amongst family members. Syed is a serial entrepreneur, his education and training in India, UK, Canada and the US, and professional career speak for themselves."

© Scoop Media

Business Headlines | Sci-Tech Headlines


Paymark: Lockdown Equals Slowdown For Some

The three days of lockdown for Auckland earlier this month made a clear impression on our retail spending figures. While only Auckland moved into Level 3 lockdown, the impact was felt across the country, albeit at different levels. Looking at the ... More>>

Infrastructure Commission: Te Waihanga Releases Report On Water Infrastructure

The New Zealand Infrastructure Commission, Te Waihanga’s latest discussion document highlights the importance of current reforms in the water sector. Its State of Play discussion document about water infrastructure is one of a series looking at the ... More>>

Sci-Tech: Perseverance Rover Lands On Mars – Expert Reaction

NASA has landed a car-sized rover on the red planet to search for signs of past life. The vehicle has more instruments than the four rovers preceding it, and it’s also carrying gear that could help pave the way for human exploration of Mars. The ... More>>


ASB: Quarterly Economic Forecast Predicts OCR Hike As Early As August 2022

Predictions of interest rate rises have been brought forward 12 months in ASB’s latest Quarterly Economic Forecast. Chief Economist Nick Tuffley now expects the RBNZ to begin raising the OCR from its current level of 0.25% as early as August ... More>>

ACT: Matariki Almost A Half Billion Dollar Tax On Business

“Official advice to the Government says an extra public holiday at Matariki could cost almost $450 million,” ACT Leader David Seymour can reveal. “This is a perfect example of the Prime Minister doing what’s popular versus what’s responsible. ... More>>

Genesis: Assessing 6,000 GWh Of Renewable Generation Options For Development By 2025

Genesis is assessing 6,000 GWh of renewable generation options for development after starting a closed RFP process with 11 partners. Those invited to participate offer a range of technologies as Genesis continues to execute its Future-gen strategy to ... More>>

OECD: Unemployment Rate Stable At 6.9% In December 2020, 1.7 Percentage Points Higher Than In February 2020

The OECD area unemployment rate was stable at 6.9% in December 2020, remaining 1.7 percentage points above the level observed in February 2020, before the COVID-19 pandemic hit the labour market. [1] In December, the unemployment rate was also stable ... More>>

Stats NZ: Unemployment Drops To 4.9 Percent As Employment Picks Up

The seasonally adjusted unemployment rate dropped to 4.9 percent in the December 2020 quarter, from 5.3 percent in the September 2020 quarter, Stats NZ said today. Last quarter’s unemployment rate of 5.3 percent followed the largest increase observed ... More>>